3Rs Sharing Conference III
3Rs Sharing Conference III
Paving the Path to Regulatory Acceptance of Alternative Methods
February 27, 2014
Program Agenda
Morning Session
8:50 AM...Opening Remarks
Dale Martin, DVM, PhD, 3Rs Committee Chair, Global Head of Standards & Innovation, Animal Research & Welfare, DSAR, Sanofi
9:00...Stem Cell Derived Tissues: Applications in Toxicology and Pharmacology
Kyle Kolaja, PhD, Vice President Business Development, Cellular Dynamics
9:50...New Direction & Transformation of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
Warren Casey, PhD, DABT, Senior Toxicologist & Director, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)
10:40...Break
10:55...Panel Discussion: Key Issues and Challenges to the Implementation & Utilization of Alternative Methods
Moderator:
Michael Kastello, DVM, PhD, Vice President and Global Deputy, Animal Research and Welfare, Sanofi-Aventis US, Chief Veterinary Officer, Sanofi Group
Panelists:
Warren Casey, PhD, DABT, Senior Toxicologist & Director, NICEATM
Michael Graziano, PhD, DABT, Vice President Drug Safety Evaluation, Bristol-Myers Squibb
Abigal Jacobs, PhD, Associate Director of Pharmacology/Toxicology for the FDA, Center for Drug Evaluation & Research
Matt Martin, PhD, Research Biologist, USEPA, Office of Research & Development, National Center for Computational Toxicology
12:00 PM...Lunch
Afternoon Session
1:00 – 3:00 PM Special Tracks
Toxicology Session
Facilitator
Lauren Hutchison, PhD, Senior Research Scientist, Product Safety, Colgate Palmolive
Regulator
Matt Martin, PhD, USEPA
Getting more data from few animals: Innovative strategies for mammalian toxicity testing
Lynea Murphy, PhD, Associate Toxicology Manager, Mammalian Toxicology Group, Toxicology & Environmental Research and Consulting, The Dow Chemical Company
Cardiac Stem Cells for Safety Pharmacology Application
Kyle Kolaja, Vice President, Business Development, Cellular Dynamics
ToxCast Phase II Data & 3Rs Implications
Matt Martin, PhD, Research Biologist, USEPA, Office of Research & Development, NCCT
DMPK Session
Facilitator
Graham Lockwood, PhD, Associate Vice President, Disposition, Safety and Animal Research, Sanofi
Regulators
Warren Casey, PhD, NICEATM
Abigail Jacobs, PhD, FDA CDER
Microsampling - When less should have been more: One company’s experience bridging concept to execution
Alan Stokes, PhD, Interim Head of Toxicology, RTP, GlaxoSmithKline
Development of approaches for efficient and animal-sparing cardiovascular risk assessment in early drug discovery
Charles Thompson, PhD, Executive Director, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories
Optimizing in vivo studies and determination of safe starting dose during drug development: Doing better with less
Arijit Chakravarty, Senior Scientist II, Head of Modeling and Simulation (DMPK), Takeda Pharmaceuticals
3:10...Session Summaries & Closing Remarks
Registration Options and Fees
|
In-Person - NJABR or SUBR Members |
$125.00 |
|
In-Person - Non-NJABR Member |
$175.00 |
|
Online - Individual (NJABR Member or Non-Member) Provides online access for one computer. |
$95.00 |
|
Online - Single Site Group Provides online access for multiple participants at one corporate facility |
$275.00 |
|
Online - Global Corporate Provides online access for an unlimited number of computers at all corporate facilities. |
$800.00 |
|
Gold Corporate Sponsorship* Includes 8 Registrations and recognition on conference printed materials. |
$2000.00 |
|
Silver Corporate Sponsorship* Includes 4 Registrations and recognition on conference printed materials. |
$1000.00 |
|
Bronze Corporate Sponsorship* Includes 1 Registration and recognition on conference printed materials. |
$500.00 |
*Sponsorship registrations can be used for either in-person or online participation.